Immatics Is A Clinical Stage Biopharmaceutical Company Founded In 2000Originating From The University Of Ta Bingen In Germanythe Company Specializes In Developing T Cell Redirecting Immunotherapies Aimed At Treating Cancerimmatics Focuses On Leveraging The Immune System To Target And Eliminate Tumor Cells Through Innovative Peptide Based Vaccines And T Cell Therapies The Company Offers A Variety Of Services And Productsincluding T Cell Redirecting Immunotherapies That Utilize Its Proprietary Xpresident Platform To Identify Tumor Associated Peptide Hla Targetsimmatics Has Developed Peptide Based Vaccine Candidatessuch As Ima901Which Have Shown Promise In Clinical Trials For Advanced Renal Cell Carcinomaadditionallythe Company Is Advancing Adoptive Cell Therapy Approachesincluding Actologactengineand Actalloto Enhance T Cell Therapy Effectiveness Against Various Cancers Immatics Has Formed Strategic Partnerships With Major Pharmaceutical Companies And Research Institutionsincluding Collaborations With Md Anderson Cancer Center And Merck Kgaathe Company Went Public In 2020 Through A Merger With A Special Purpose Acquisition Companyraising Approximately A 135 Million To Support Its Development Efforts
No conferences found for this company.
| Company Name | Immatics Biotechnologies Gmbh |
| Country |
Germany
|
| Address | N/A |
| Telephone | N/A |
| N/A |
